Forte Biosciences (NASDAQ:FBRX – Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Forte Biosciences to post earnings of ($0.89) per share for the quarter.
Forte Biosciences Stock Up 2.4 %
FBRX stock opened at $6.38 on Friday. Forte Biosciences has a 52 week low of $4.11 and a 52 week high of $28.68. The business has a 50-day simple moving average of $6.62 and a 200 day simple moving average of $11.74. The company has a market cap of $42.00 million, a PE ratio of -0.39 and a beta of 2.82.
Analysts Set New Price Targets
Several brokerages have recently commented on FBRX. TD Cowen began coverage on shares of Forte Biosciences in a research report on Tuesday, January 21st. They issued a “buy” rating for the company. Chardan Capital decreased their price objective on shares of Forte Biosciences from $64.00 to $61.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st.
Forte Biosciences Company Profile
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
See Also
- Five stocks we like better than Forte Biosciences
- Which Wall Street Analysts are the Most Accurate?
- Google Is Betting Big on Nuclear Reactors—Should You?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs
- 3 Stocks to Consider Buying in October
- Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
